Socioeconomic and structural barriers to addressing obesity in communities: a scientific statement from the American Heart Association
Chung ST, Harrington J, Kandula NR, et al.
Circulation. Pub. online 15 Jan 2026.
Leggi
2025 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline for the primary care management of chronic kidney disease
Schwartz AR, Sosnov J, Brown J, et al.
Ann Intern Med. Pub. online 30 Dec 2025.
Leggi
Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes
Karakus KE, Chesshir L, Walker S, et al.
Diabetologia. Pub. online 15 Jan 2026.
Leggi
Weight regain after cessation of medication for weight management: systematic review and meta-analysis
West S, Scragg J, Aveyard P, et al.
BMJ. Pub. online 7 Jan 2026.
Leggi
FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications: FDA’s evaluation did not identify an increased risk of suicidal ideation or behavior with the use of GLP-1 RA medications
13 gennaio 2026
Leggi
European Commission: Teizeild (Teplizumab) is indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and paediatric patients 8 years of age and older with stage 2 T1D
9 gennaio 2026
Leggi
MiniMed 780G advanced hybrid closed-loop system use during days without user-initiated boluses
Niu F, Liu M, Yovanovich C, et al.
Diabetes Care. Pub. online 7 Jan 2026.
Leggi
Associations of moderate-to-vigorous physical activity timing with type 2 diabetes incidence in UK Biobank and prevalent glycemic measures in NHANES
Feng Q, Albalak G, Ao L, et al.
Diabetes Care. Pub. online 9 Jan 2026.
Leggi